Literature DB >> 2931247

A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels.

H Kuhl, G Gahn, G Romberg, W März, H D Taubert.   

Abstract

The effect of a low-dose triphasic oral contraceptive (OC) containing ethinyl estradiol and levonorgestrel (EE/NG) upon serum levels of endogenous sexual hormones was compared to that of a preparation containing EE and desogestrel (EE/DG). Blood samples were taken on Day 6, 11, 21, and 28 of a control cycle and of the third cycle of treatment with either the EE/NG or EE/DG preparation (11 volunteers each). After a washout period of 3 months, the contraceptives were changed in a cross-over fashion. Blood samples were again taken on Day 6, 11, 21, and 28 of the third washout cycle and the third treatment cycle. There was no significant suppression of serum LH and FSH during treatment with EE/NG and EE/DG except on Day 21, while estradiol levels were significantly lowered. Similar to the gonadotropin concentrations, the estrogen levels showed great individual variations; although they were depressed in the majority of the women, there was a considerable stimulation of follicular activity in 36% of the women under EE/NG and 18% under EE/DG. Both EE/NG and EE/DG suppressed significantly serum progesterone, testosterone, and DHEA-S, while prolactin was unaffected. In three cases an escape ovulation seemed to have occurred, but no pregnancy was observed. The spottings (8/22 women) and breakthrough bleedings (6/22 women) did not correlate with the serum levels of estradiol. The results indicate that the suppression of gonadotropin secretion during treatment with low-dose OC is a time-dependent process which in some women may be at or below the threshold of safe ovulation inhibition.

Entities:  

Keywords:  Biology; Clinical Research; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Contraceptive Mode Of Action; Endocrine System; Ethinyl Estradiol; Evaluation; Family Planning; Follicle Stimulating Hormone; Gonadotropins; Gonadotropins, Pituitary; Hormones; Levonorgestrel; Luteinizing Hormone; Oral Contraceptives; Oral Contraceptives, Low-dose; Ovulation; Ovulation Suppression; Physiology; Reproduction; Reproductive Control Agents; Research Methodology

Mesh:

Substances:

Year:  1985        PMID: 2931247     DOI: 10.1016/0010-7824(85)90058-7

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  6 in total

Review 1.  Triphasic versus monophasic oral contraceptives for contraception.

Authors:  Huib A A M Van Vliet; David A Grimes; Laureen M Lopez; Kenneth F Schulz; Frans M Helmerhorst
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

Review 2.  Long-cycle treatment with oral contraceptives.

Authors:  Inka Wiegratz; Herbert Kuhl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.

Authors:  Murray Joseph Casey; Todd A Salzman
Journal:  Linacre Q       Date:  2018-07-20

4.  Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill.

Authors:  Maurizio Guida; Giuseppe Bifulco; Attilio Di Spiezio Sardo; Mariamaddalena Scala; Loredana Maria Sosa Fernandez; Carmine Nappi
Journal:  Int J Womens Health       Date:  2010-08-24

Review 5.  Ovarian follicular development during the use of oral contraception: a review.

Authors:  Angela R Baerwald; Roger A Pierson
Journal:  J Obstet Gynaecol Can       Date:  2004-01

Review 6.  The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis.

Authors:  Y Zimmerman; M J C Eijkemans; H J T Coelingh Bennink; M A Blankenstein; B C J M Fauser
Journal:  Hum Reprod Update       Date:  2013-09-29       Impact factor: 15.610

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.